Takeda tags another Shire drug for sale to win key nod for $62B deal
admin 29th October 2018 Uncategorised 0Amid reports that it is aiming to sell Shire’s Xiidra and Natpara to pay down deal-related debt, Takeda has proposed jettisoning another piece of Shire’s portfolio. The phase 3 inflammatory bowel disease candidate SHP647, which could overlap with Takeda’s own blockbuster Entyvio, would go on the block to appease European antitrust regulators.
More: Takeda tags another Shire drug for sale to win key nod for B deal
Source: fierce